Terminated study’s ‘challenges’ may guide future trials of MRD-guided breast cancer therapy

SAN ANTONIO — A randomized phase 3 clinical trial designed to assess whether circulating tumor DNA surveillance could be used to help prevent breast cancer recurrence closed early due to a lack of patients eligible for randomization.
Still, the “challenges” encountered in the ZEST study could help inform how future clinical trials of minimal residual disease (MRD)-guided therapy in breast cancer are conducted, according to researcher Nicholas Turner, MD, PhD, director of clinical research and development at The Royal Marsden Hospital and Institute of Cancer Research in

SAN ANTONIO — A randomized phase 3 clinical trial designed to assess whether circulating tumor DNA surveillance could be used to help prevent breast cancer recurrence closed early due to a lack of patients eligible for randomization.
Still, the “challenges” encountered in the ZEST study could help inform how future clinical trials of minimal residual disease (MRD)-guided therapy in breast cancer are conducted, according to researcher Nicholas Turner, MD, PhD, director of clinical research and development at The Royal Marsden Hospital and Institute of Cancer Research in